Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: insights from a clinical case series
Authors:
- Ana Silvia Sobreira Lima VerdeAVAna Silvia Sobreira Lima Verde
- Alessandra Braga Cruz Guedes de MoraisAMAlessandra Braga Cruz Guedes de Morais
- Amanda Vale CatundaACAmanda Vale Catunda
- João Igor Dantas LandimJLJoão Igor Dantas Landim
- Ian Silva RibeiroIRIan Silva Ribeiro
- Bruno Diógenes IepsenBIBruno Diógenes Iepsen
- Norberto Anízio Ferreira FrotaNFNorberto Anízio Ferreira Frota
Open Access
- 15 July 2025
- journal article
- case report
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (12) , 001-006
Abstract
Cerebral amyloid angiopathy (CAA) is a small vessel disease characterized by the deposition of amyloid-beta in small cerebral vessels, which can lead to intracerebral hemorrhages and cognitive impairment. Rare variants, such as cerebral amyloid angiopathy-related inflammation (CAA-ri) and iatrogenic CAA (ICAA), may mimic other neurological conditions and challenge diagnosis in clinical practice. We present three cases that illustrate distinct CAA syndromes, along with CSF biomarker analysis. One patient experienced recurrent hemorrhagic strokes with a history of dural graft, raising concerns about amyloid transmission. Two patients presented with rapidly progressive dementia that fulfilled CAA-ri criteria. All cases exhibited decreased levels of CSF Aβ40 and Aβ42, with one showing elevated p-tau, suggesting comorbid Alzheimer's pathology. Cerebrospinal fluid biomarkers complement neuroimaging in the diagnosis of CAA, aiding in differentiation from other dementias. Early recognition and diagnosis of CAA-ri variants is crucial, because immunotherapy may improve outcomes. Further research is necessary to establish biomarker thresholds and their clinical applicability.Keywords
This publication has 12 references indexed in Scilit:
- Core CSF Biomarker Profile in Cerebral Amyloid AngiopathyNeurology, 2024
- Cerebrospinal fluid biomarkers for cerebral amyloid angiopathyBrain Communications, 2023
- Iatrogenic Cerebral Amyloid Angiopathy Post Neurosurgery: Frequency, Clinical Profile, Radiological Features, and OutcomeStroke, 2023
- Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid AngiopathyAnnals of Neurology, 2023
- The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy studyThe Lancet Neurology, 2022
- Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenonJournal of Neurology, Neurosurgery & Psychiatry, 2022
- Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related InflammationNeurology, 2021
- Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysisAlzheimer's & Dementia, 2021
- Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy–Related InflammationJAMA Neurology, 2016
- Anti–amyloid β autoantibodies in cerebral amyloid angiopathy–related inflammation: Implications for amyloid‐modifying therapiesAnnals of Neurology, 2013